CWD vs ARES vs CSWC vs TPVG vs RCUS

For growth investors, Ares Management Corporation (ARES) is the stronger pick with 66.

6% revenue growth year-over-year, versus -43. 8% for CaliberCos Inc. (CWD). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 9x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate Ares Management Corporation (ARES) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TriplePoint Venture Growth BDC Corp.

(TPVG) is the cheapest at 4. 9x versus Ares Management Corporation at 62. 8x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Ares Management Corporation wins at 1. 15x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x — a reasonable growth-adjusted valuation.

Over the past 5 years, Ares Management Corporation (ARES) delivered a total return of +160.

2%, compared to -99. 4% for CaliberCos Inc. (CWD). Over 10 years, the gap is even starker: ARES returned +929. 6% versus CWD's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TriplePoint Venture Growth BDC Corp.

(TPVG) is the lower-risk stock at 0. 83β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 135% more volatile than TPVG relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 7% for CaliberCos Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ares Management Corporation (ARES) is pulling ahead at 66.

6% versus -43. 8% for CaliberCos Inc. (CWD). On earnings-per-share growth, the picture is similar: TriplePoint Venture Growth BDC Corp. grew EPS 48. 8% year-over-year, compared to -42. 9% for CaliberCos Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Ares Management Corporation (ARES) is the more undervalued stock at a PEG of 1. 15x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 6. 5x forward P/E versus 20. 2x for Ares Management Corporation — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TPVG: 49. 4% to $8. 95.

In this comparison, TPVG (17.

1% yield), CSWC (10. 2% yield), ARES (6. 6% yield) pay a dividend. CWD, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Capital Southwest Corporation (CSWC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

84), 10. 2% yield, +234. 2% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CSWC: +234. 2%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CWD (Financial Services) and ARES (Financial Services) and CSWC (Financial Services) and TPVG (Financial Services) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CWD is a small-cap quality compounder stock; ARES is a mid-cap high-growth stock; CSWC is a small-cap deep-value stock; TPVG is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. ARES, CSWC, TPVG pay a dividend while CWD, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.